

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2A
HB
6/5/02

Applicant: Jack L. Arbiser

Serial No: Continuation of 09/345,712

Express Mail Label
No. EL 709 418 650 US

Filed: January 18, 2001

Date of Deposit: January 18, 2001

For: CURCUMIN AND CURCUMINOID INHIBITION OF ANGIOGENESIS

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination, please amend the application as follows.

In the Specification

On page 1, after the title and before "Background of the Invention", please insert the following paragraph:

--This application is a continuation of copending application U.S. Serial No. 09/345,712 filed June 30, 1999, entitled "*Curcumin and Curcuminoid Inhibition of Angiogenesis*", by Jack L. Arbiser.--

In the Claims

Please cancel claims 1-3.

4. (amended) A method for inhibiting skin disorders selected from the group consisting of lymphangiogenesis, [hemangioma of childhood,] Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, [pyogenic granulomas,] recessive dystrophic epidermolysis bullosa, venous ulcers, [acne,] rosacea, eczema, molluscum contagious, seborrheic

A2 keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis.

Please cancel claims 7-9.

A3 13. (amended) A pharmaceutical composition comprising a curcumin in combination with a pharmaceutically acceptable carrier for topical administration, wherein the curcumin is present in a dosage effective to treat a condition selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis, wherein the carrier is an ointment containing between one-half percent (0.5%) and five percent (5%) of the curcuminoid or a polymer formulation for implantation.

14. (amended) The composition of claim 13 wherein the carrier is an ointment [or gel].

15. (amended) The composition of claim 14 as an ointment [or hydrogel] containing between one-half percent (0.5%) and five percent (5%) of the curcuminoid.

16. The composition of claim 13 wherein the carrier is a polymer formulation for implantation.

Sub 17. (new) A method for inhibiting skin disorders selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis, wherein the angiogenesis inhibitor is selected from the group consisting of

Continuation of U.S.S.N. 09/345,712
Filed: January 18, 2001
PRELIMINARY AMENDMENT
Express Mail Label No. EL 709 418 650 US
Date of Deposit: January 18, 2001

tetracyclines inhibiting collagenase,
endostatin,
a sulfated polysaccharide which inhibits angiogenesis.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: January 18, 2001

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)